Arix Bioscience Share Forecast, Price & News

GBX 176
-9.00 (-4.86 %)
(As of 06/18/2021 04:35 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume142,911 shs
Average Volume241,728 shs
Market Capitalization£232.28 million
P/E Ratio1.98
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Arix Bioscience and its competitors with MarketBeat's FREE daily newsletter.

About Arix Bioscience

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.84 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Arix Bioscience (LON:ARIX) Frequently Asked Questions

Is Arix Bioscience a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arix Bioscience in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Arix Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARIX, but not buy additional shares or sell existing shares.
View analyst ratings for Arix Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Arix Bioscience?

Wall Street analysts have given Arix Bioscience a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arix Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Arix Bioscience's stock been impacted by Coronavirus?

Arix Bioscience's stock was trading at GBX 77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARIX shares have increased by 128.6% and is now trading at GBX 176.
View which stocks have been most impacted by COVID-19

Who are Arix Bioscience's key executives?

Arix Bioscience's management team includes the following people:
  • Mr. Robert Lyne, Interim CEO, Gen. Counsel, Company Sec. & Director
  • Mr. Marcus Karia, Group Fin. Director
  • Ms. Charlotte Parry, Head of Investor Relations
  • Dr. Christian Schetter, Managing Director (Age 57)
  • Mr. John Cassidy Ph.D., Principal
  • Mr. Tim Xu M.D., Principal
  • Mr. Noor Lalani, Public Markets Investment Director
  • Ms. Michelle Keating, Financial Controller
  • Dr. Gita Dittmar, Venture Partner
  • Mr. Felix Breyer Ph.D., Investment Analyst

Who are some of Arix Bioscience's key competitors?

What is Arix Bioscience's stock symbol?

Arix Bioscience trades on the London Stock Exchange (LON) under the ticker symbol "ARIX."

How do I buy shares of Arix Bioscience?

Shares of ARIX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Arix Bioscience's stock price today?

One share of ARIX stock can currently be purchased for approximately GBX 176.

How much money does Arix Bioscience make?

Arix Bioscience has a market capitalization of £232.28 million and generates £135.77 million in revenue each year.

How many employees does Arix Bioscience have?

Arix Bioscience employs 12 workers across the globe.

What is Arix Bioscience's official website?

The official website for Arix Bioscience is arixbioscience.com.

Where are Arix Bioscience's headquarters?

Arix Bioscience is headquartered at 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom.

How can I contact Arix Bioscience?

Arix Bioscience's mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The company can be reached via phone at +44-20-72901050.

This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.